Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod

被引：2
作者：
Morales, Raquel Pinar [1 ,2 ]
Carrasco Garcia, Maria [1 ]
Gutierrez-Rojas, Luis [2 ,3 ]
Barrero Hernandez, Francisco Javier [1 ,2 ]
机构：
[1] Hosp Clin Univ San Cecilio, Serv Neurol, Granada, Spain
[2] Univ Granada, Dept Med, Granada, Spain
[3] Hosp Clin Univ San Cecilio, Unidad Salud Mental, Granada, Spain
来源：
CASE REPORTS IN NEUROLOGY | 2022年 / 14卷 / 01期
关键词：
Fingolimod; Immune reconstitution inflammatory syndrome; Magnetic resonance imaging; Multiple sclerosis; Progressive multifocal leukoencephalopathy; PML; MRI; MS;
D O I：
10.1159/000521944
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Progressive multifocal leukoencephalopathy (PML) is a rare complication of immunosuppressive treatment in MS patients. Immune reconstitution inflammatory syndrome (IRIS) appears after the withdrawal of certain drugs such as natalizumab (NTZ) or fingolimod. The development of PML-IRIS after NTZ treatment has been described, and its diagnosis is made by clinical and radiological criteria and the determination of the John Cunningham virus in CSF. We present a clinical case of a patient with MS who, after the withdrawal of fingolimod, developed PML-IRIS despite sustained lymphopenia. This is important for pharmacovigilance purposes, not only for NTZ but also for alternative drugs used in MS treatment.
引用
收藏
页码：38 / 43
页数：6
相关论文
共 14 条
[1]   Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS) [J].
Bauer, Jan ;
Gold, Ralf ;
Adams, Ortwin ;
Lassmann, Hans .
ACTA NEUROPATHOLOGICA, 2015, 130 (06) :751-764
[2]   Progressive multifocal leukoencephalopathy after fingolimod treatment [J].
Berger, Joseph R. ;
Cree, Bruce A. ;
Greenberg, Benjamin ;
Hemmer, Bernhard ;
Ward, Brian J. ;
Dong, Victor M. ;
Merschhemke, Martin .
NEUROLOGY, 2018, 90 (20) :E1815-E1821
[3]   Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy [J].
Francis, G. ;
Kappos, L. ;
O'Connor, P. ;
Collins, W. ;
Tang, D. ;
Mercier, F. ;
Cohen, J. A. .
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (04) :471-480
[4]   Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities [J].
Honce, Justin M. ;
Nagae, Lidia ;
Nyberg, Eric .
MULTIPLE SCLEROSIS INTERNATIONAL, 2015, 2015
[5]   Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications [J].
Igra, Mark S. ;
Paling, David ;
Wattjes, Mike P. ;
Connolly, Daniel J. A. ;
Hoggard, Nigel .
BRITISH JOURNAL OF RADIOLOGY, 2017, 90 (1074)
[6]   Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients [J].
Jordan, Allison L. M. ;
Yang, Jennifer ;
Fisher, Caitlyn J. ;
Racke, Michael K. ;
Mao-Draayer, Yang .
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (01) :7-15
[7]   PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation [J].
Killestein, J. ;
Vennegoor, A. ;
van Golde, A. E. L. ;
Bourez, R. L. J. H. ;
Wijlens, M. L. B. ;
Wattjes, M. P. .
CASE REPORTS IN NEUROLOGICAL MEDICINE, 2014, 2014
[8]   Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab [J].
Langer-Gould, A ;
Atlas, SW ;
Green, AJ ;
Bollen, AW ;
Pelletier, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :375-381
[9]   Three cases of non-carryover fingolimod-PML Is the risk in Japan increased? [J].
Nakahara, Jin ;
Tomaske, Laura ;
Kume, Kodai ;
Takata, Tadayuki ;
Kamada, Masaki ;
Deguchi, Kazushi ;
Kufukihara, Kenji ;
Schneider, Ruth ;
Gold, Ralf ;
Ayzenberg, Ilya .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (03)
[10]   Fingolimod-associated PML with mild IRIS in MS A clinicopathologic study [J].
Nishiyama, Shuhei ;
Misu, Tatsuro ;
Shishido-Hara, Yukiko ;
Nakamichi, Kazuo ;
Saijo, Masayuki ;
Takai, Yoshiki ;
Takei, Kentarou ;
Yamamoto, Naoki ;
Kuroda, Hiroshi ;
Saito, Ryuta ;
Watanabe, Mika ;
Tominaga, Teiji ;
Nakashima, Ichiro ;
Fujihara, Kazuo ;
Aoki, Masashi .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2018, 5 (01)
12